A	B	C	D	E	F
1	Main
2		Brand	VK2735
3		Molecule	Peptide
4		Patents	11744873
5		Clinical Trials
6			Phase II "VENTURE"
7				13 weeks	lbs	Vomiting
8			Placebo	-1.8	-3.9600000000000004	0
9			2.5mg	-9.2	-20.24	0.09
10			5.0mg	-10.7	-23.54	0.17
11			10mg	-13.3	-29.260000000000005	0.17
12			15mg	-14.6	-32.120000000000005	0.29
13
14			Nausea	0.43	(68% mild, 32% moderate)
15			Vomiting	0.18
16
17
18
19			Phase III "SURMOUNT-1" - Mounjaro vs. placebo in obesity - NEJM 2022 - NCT04184622
20				20 weeks	Nausea	Vomiting
21			Pooled	-12.8
22			Placebo	-2.7
23			5mg		0.25	0.08
24			10mg		0.33	0.11
25			15mg		0.31	0.12